ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The Effects of Donor Specific Anti- Human Leukocyte Antigen Antibodies Late After Heart Transplantation

M. Kittleson, J. Patel, F. Liou, S. Siddiqui, A. Fong, M. Johnson, D. Chang, L. Czer, F. Esmailian, N. Reinsmoen, J. Kobashigawa.

Cedars-Sinai Heart Institute, Los Angeles, CA.

Meeting: 2015 American Transplant Congress

Abstract number: D261

Keywords: Immunoglobulins (Ig), Vascular disease

Session Information

Date: Tuesday, May 5, 2015

Session Name: Poster Session D: "The Tell-Tale Heart": Allograft Rejection and Post-Transplant Monitoring

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Effects of Anti-Human Leukocyte Antigen Antibody After Heart Transplantation
  • Is There a Protective Value for Low Level Donor Specific Antibodies to Prevent Cardiac Allograft Vasculopathy After Heart Transplant?

Purpose: The development of anti-HLA antibodies following heart transplantation has been associated with poor outcomes, including lower survival and increased risk for the development of cardiac allograft vasculopathy (CAV). It is known that anti-HLA antibodies may develop more than a year after heart transplantation but it is not known whether these antibodies have clinical relevance.

Methods: Between 2009 and 2013, we reviewed 71 heart transplant patients were found to have donor specific antibodies (DSA) early versus late after heart transplant. Late antibodies were defined as antibodies that developed after 1 year post-transplant. Subsequent 1 year survival, freedom from cardiac allograft vasculopathy (CAV), and freedom from rejection were then assessed.

Results: Those patients who developed late DSA (at a mean time of 29.2 ± 10.3 months post-transplant) have a lower freedom from biopsy negative rejection in the ensuing year after detection of the initial antibody compared to those patients who developed early DSAs (at a mean time of 1.7 ± 3.3 months post-transplant). However, patients who developed late DSA did not appear to have worse outcomes in terms of 1-year subsequent actuarial survival, freedom from CAV, any-treated rejection, treated cellular rejection and treated antibody-mediated rejection compared to those who developed early DSA (see table).

Endpoints Early DSA (n=59) Late DSA (n=12) P-Value
1-Year Subsequent Actuarial Survival 96.6% 100.0% 0.522
1-Year Subsequent Actuarial Freedom from CAV 93.7% 79.5% 0.161
1-Year Subsequent Actuarial Freedom from Any Treated Rejection 78.3% 66.7% 0.276
1-Year Subsequent Actuarial Freedom from Treated Cellular Rejection 81.9% 91.7% 0.461
1-Year Subsequent Actuarial Freedom from Antibody Mediated Rejection 88.1% 83.3% 0.669
1-Year Subsequent Actuarial Freedom from Antibody Mediated Rejection 98.3% 70.7% 0.001
Early = Less than 1 Year Post Transplant
Late = Greater than 1 Year Post Transplant

Conclusion: Late DSA development may be a marker for the development of biopsy negative rejection. However, subsequent survival and development of CAV, treated cellular rejection, and treated antibody mediated rejection do not appear to be affected. Longer follow-up with larger numbers will be needed to confirm these results.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kittleson M, Patel J, Liou F, Siddiqui S, Fong A, Johnson M, Chang D, Czer L, Esmailian F, Reinsmoen N, Kobashigawa J. The Effects of Donor Specific Anti- Human Leukocyte Antigen Antibodies Late After Heart Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/the-effects-of-donor-specific-anti-human-leukocyte-antigen-antibodies-late-after-heart-transplantation/. Accessed January 22, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
    • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.